We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inogen (INGN) Q3 Earnings Miss Estimates, Revenues Down Y/Y
Read MoreHide Full Article
Inogen, Inc. (INGN - Free Report) incurred an adjusted loss per share of 36 cents for third-quarter 2023, wider than the adjusted loss per share of 18 cents in the year-ago period. The Zacks Consensus Estimate was pegged at a loss of 57 cents per share.
GAAP loss per share for the quarter was $1.97, wider than the year-earlier loss of 42 cents per share.
Revenues in Detail
Inogen registered revenues of $83.9 million for the third quarter, down 20.3% year over year. The figure surpassed the Zacks Consensus Estimate by 3.8%.
On a constant-currency basis, total revenues for the reported quarter decreased 21.5%.
Per management, the year-over-year decrease in the top line primarily resulted from lower domestic business-to-business sales and lower direct-to-consumer revenues. However, this was partially offset by strong growth in rental and international business-to-business sales.
Segmental Details
Inogen derives revenues from two sources — rental and sales.
Rental revenues for the reported quarter grossed $15.9 million, up 8.7% from the year-ago period. Per management, an increase in the total number of rental patients on service resulted in the upside. This figure compares to our Rental revenues’ third-quarter projection of $13.1 million.
Sales revenues were $67.9 million, down 25% from the prior-year quarter. This figure compares to our Sales revenues’ third-quarter projection of $67.2 million.
Revenues by Region & Category
Domestic business-to-business sales for third-quarter 2023 amounted to $17.3 million, down 59.4% on a year-over-year basis. Our projection for the same was $34.7 million.
International business-to-business sales for the reported quarter amounted to $25.6 million, up 69.8% year over year on a reported basis and up 62% on a constant-currency basis. Our model estimate for the metric was $15.2 million.
Domestic direct-to-consumer sales decreased 24.1% year over year to $25.1 million for the quarter. Our estimate for the same was $17.3 million.
For the quarter under review, Inogen’s adjusted gross profit fell 18.6% from the year-ago period to $37.1 million. However, the adjusted gross margin expanded 96 basis points to 44.2%.
Sales and marketing expenses decreased 22.7% from the year-ago quarter to $26.1 million. Research and development expenses decreased 2% year over year to $4.5 million, while general and administrative expenses increased 15.1% to $17 million. Adjusted operating expenses of $47.6 million decreased 10.4% year over year.
Adjusted operating loss totaled $10.5 million compared with the prior-year quarter’s adjusted operating loss of $7.5 million.
Financial Position
Inogen exited third-quarter 2023 with cash and cash equivalents of $124.6 million compared with $167.7 million at the second-quarter end.
The company ended the quarter with no debt on its balance sheet.
Cumulative net cash used in operating activities at the end of third-quarter 2023 was $0.1 million compared with $22.1 million a year ago.
Guidance
Inogen has reiterated its revenue outlook for the full year.
The company continues to expect its total revenues between $315 million and $320 million. The Zacks Consensus Estimate currently stands at $317.7 million.
Our Take
Inogen exited the third quarter of 2023 with better-than-expected revenues. The robust year-over-year uptick in rental revenues and international business-to-business sales was impressive. The expansion of the adjusted gross margin also bodes well.
In September, Inogen completed the acquisition of Physio-Assist SAS, which expanded its global respiratory care presence by addressing a sizeable, growing and underserved airway clearance market opportunity. On the earnings call, management confirmed that it secured the reimbursement approval for Rove 6 in France in August. Inogen is currently focused on introducing Rove 6 to key customers in that market. These developments look promising for the stock.
Yet, wider-than-expected loss per share and dismal year-over-year top-line and bottom-line performances were worrying. A decline in domestic business-to-business and domestic direct-to-consumer sales was concerning as well. Inogen continued to incur operating losses for the third quarter, which did not bode well.
Zacks Rank and Key Picks
Inogen currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories (ABT - Free Report) , DexCom, Inc. (DXCM - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted earnings per share (EPS) of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2.
DexCom has a long-term estimated growth rate of 33.6%. DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%.
Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Inogen (INGN) Q3 Earnings Miss Estimates, Revenues Down Y/Y
Inogen, Inc. (INGN - Free Report) incurred an adjusted loss per share of 36 cents for third-quarter 2023, wider than the adjusted loss per share of 18 cents in the year-ago period. The Zacks Consensus Estimate was pegged at a loss of 57 cents per share.
GAAP loss per share for the quarter was $1.97, wider than the year-earlier loss of 42 cents per share.
Revenues in Detail
Inogen registered revenues of $83.9 million for the third quarter, down 20.3% year over year. The figure surpassed the Zacks Consensus Estimate by 3.8%.
On a constant-currency basis, total revenues for the reported quarter decreased 21.5%.
Per management, the year-over-year decrease in the top line primarily resulted from lower domestic business-to-business sales and lower direct-to-consumer revenues. However, this was partially offset by strong growth in rental and international business-to-business sales.
Segmental Details
Inogen derives revenues from two sources — rental and sales.
Rental revenues for the reported quarter grossed $15.9 million, up 8.7% from the year-ago period. Per management, an increase in the total number of rental patients on service resulted in the upside. This figure compares to our Rental revenues’ third-quarter projection of $13.1 million.
Sales revenues were $67.9 million, down 25% from the prior-year quarter. This figure compares to our Sales revenues’ third-quarter projection of $67.2 million.
Revenues by Region & Category
Domestic business-to-business sales for third-quarter 2023 amounted to $17.3 million, down 59.4% on a year-over-year basis. Our projection for the same was $34.7 million.
International business-to-business sales for the reported quarter amounted to $25.6 million, up 69.8% year over year on a reported basis and up 62% on a constant-currency basis. Our model estimate for the metric was $15.2 million.
Domestic direct-to-consumer sales decreased 24.1% year over year to $25.1 million for the quarter. Our estimate for the same was $17.3 million.
Inogen, Inc Price, Consensus and EPS Surprise
Inogen, Inc price-consensus-eps-surprise-chart | Inogen, Inc Quote
Margins
For the quarter under review, Inogen’s adjusted gross profit fell 18.6% from the year-ago period to $37.1 million. However, the adjusted gross margin expanded 96 basis points to 44.2%.
Sales and marketing expenses decreased 22.7% from the year-ago quarter to $26.1 million. Research and development expenses decreased 2% year over year to $4.5 million, while general and administrative expenses increased 15.1% to $17 million. Adjusted operating expenses of $47.6 million decreased 10.4% year over year.
Adjusted operating loss totaled $10.5 million compared with the prior-year quarter’s adjusted operating loss of $7.5 million.
Financial Position
Inogen exited third-quarter 2023 with cash and cash equivalents of $124.6 million compared with $167.7 million at the second-quarter end.
The company ended the quarter with no debt on its balance sheet.
Cumulative net cash used in operating activities at the end of third-quarter 2023 was $0.1 million compared with $22.1 million a year ago.
Guidance
Inogen has reiterated its revenue outlook for the full year.
The company continues to expect its total revenues between $315 million and $320 million. The Zacks Consensus Estimate currently stands at $317.7 million.
Our Take
Inogen exited the third quarter of 2023 with better-than-expected revenues. The robust year-over-year uptick in rental revenues and international business-to-business sales was impressive. The expansion of the adjusted gross margin also bodes well.
In September, Inogen completed the acquisition of Physio-Assist SAS, which expanded its global respiratory care presence by addressing a sizeable, growing and underserved airway clearance market opportunity. On the earnings call, management confirmed that it secured the reimbursement approval for Rove 6 in France in August. Inogen is currently focused on introducing Rove 6 to key customers in that market. These developments look promising for the stock.
Yet, wider-than-expected loss per share and dismal year-over-year top-line and bottom-line performances were worrying. A decline in domestic business-to-business and domestic direct-to-consumer sales was concerning as well. Inogen continued to incur operating losses for the third quarter, which did not bode well.
Zacks Rank and Key Picks
Inogen currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories (ABT - Free Report) , DexCom, Inc. (DXCM - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted earnings per share (EPS) of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2.
DexCom has a long-term estimated growth rate of 33.6%. DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%.
Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.